Calimmune is a clinical-stage biotechnology company focused on developing novel gene therapies that have the potential to improve and protect the lives of patients. Our lead development programs are novel outpatient ex vivo gene therapies for hematologic diseases.

Preview or Download Pipeline Graphic

Immunotherapy programs address widespread diseases with high unmet medical need

Scroll to view more

Information about our CAL-1 clinical trial can be found by visiting clinicaltrials.gov and referencing identifier #NCT02390297